A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Conditions:   Pancreatic Adenocarcinoma;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma;   Mesothelioma;   Non-squamous Non-small-cell Lung Cancer;   Triple Negative Breast Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma Interventions:   Drug: TAK-500;   Drug: Pembrolizumab Sponsor:   Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials